{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:24:50Z","timestamp":1793384690592,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH\/NCI","award":["NIH\/NCI Cancer Center Support Grant P30 CA008748"],"award-info":[{"award-number":["NIH\/NCI Cancer Center Support Grant P30 CA008748"]}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","award":["Imaging"],"award-info":[{"award-number":["Imaging"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","award":["Radiation Sciences Program"],"award-info":[{"award-number":["Radiation Sciences Program"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sirtex Inc."},{"DOI":"10.13039\/100008497","name":"Boston Scientific Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008497","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"DOI":"10.1007\/s00270-025-04175-8","type":"journal-article","created":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T19:19:46Z","timestamp":1757445586000},"page":"73-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Tumor Absorbed Dose Predicts Survival and Local Tumor Control in Colorectal Liver Metastases Treated with 90Y Radioembolization"],"prefix":"10.1007","volume":"49","author":[{"given":"Marios-Platon","family":"Dimopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlasios S.","family":"Sotirchos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Dunne-Jaffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashara","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena N.","family":"Petre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica S.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithat","family":"Gonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devika","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise C.","family":"Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Katsanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3142-1399","authenticated-orcid":false,"given":"Constantinos T.","family":"Sofocleous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"issue":"4","key":"4175_CR1","first-page":"258","volume":"10","author":"SR Alberts","year":"2011","unstructured":"Alberts SR, Poston GJ. Treatment advances in liver-limited metastatic colorectal cancer. Clin Colorectal Cancer. 2011;10(4):258\u201365.","journal-title":"Clin Colorectal Cancer"},{"issue":"29","key":"4175_CR2","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1200\/JCO.2007.11.0833","volume":"25","author":"JS Tomlinson","year":"2007","unstructured":"Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575\u201380.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4175_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1245\/s10434-010-1288-5","volume":"18","author":"RC Martin","year":"2011","unstructured":"Martin RC, Joshi J, Robbins K, Tomalty D, Bosnjakovik P, Derner M, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011;18(1):192\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"4175_CR4","first-page":"e82","volume":"20","author":"I Kurilova","year":"2021","unstructured":"Kurilova I, Bendet A, Petre EN, Boas FE, Kaye E, Gonen M, et al. Factors associated with local tumor control and complications after thermal ablation of colorectal cancer liver metastases: a 15-year retrospective cohort study. Clin Colorectal Cancer. 2021;20(2):e82\u201395.","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"4175_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1148\/radiol.2472062029","volume":"247","author":"KT Sato","year":"2008","unstructured":"Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres\u2013safety, efficacy, and survival. Radiology. 2008;247(2):507\u201315.","journal-title":"Radiology"},{"key":"4175_CR6","doi-asserted-by":"publisher","unstructured":"Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, et al. NCCN Guidelines\u00ae Insights: Rectal Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(6):366\u2212375. https:\/\/doi.org\/10.6004\/jnccn.2024.0041. PMID: 39151454.","DOI":"10.6004\/jnccn.2024.0041"},{"issue":"3","key":"4175_CR7","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/sj.bjc.6605770","volume":"103","author":"M Cosimelli","year":"2010","unstructured":"Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, et al. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010;103(3):324\u201331.","journal-title":"Br J Cancer"},{"issue":"2","key":"4175_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.annonc.2023.10.129","volume":"35","author":"A Cervantes","year":"2024","unstructured":"Cervantes A, Martinelli E. Updated treatment recommendation for third-line treatment in advanced colorectal cancer from the ESMO metastatic colorectal cancer living guideline. Ann Oncol. 2024;35(2):241\u20133.","journal-title":"Ann Oncol"},{"key":"4175_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194908","author":"T Sankhla","year":"2021","unstructured":"Sankhla T, Cheng B, Nezami N, Xing M, Sethi I, Bercu Z, et al. Role of resin microsphere Y90 dosimetry in predicting objective tumor response, survival and treatment related toxicity in surgically unresectable colorectal liver metastasis: a retrospective single institution study. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13194908.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"4175_CR10","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","volume":"18","author":"HS Wasan","year":"2017","unstructured":"Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159\u201371.","journal-title":"Lancet Oncol"},{"issue":"15","key":"4175_CR11","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","volume":"34","author":"GA van Hazel","year":"2016","unstructured":"van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723\u201331.","journal-title":"J Clin Oncol"},{"issue":"13","key":"4175_CR12","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1002\/bjs.11283","volume":"106","author":"B Garlipp","year":"2019","unstructured":"Garlipp B, Gibbs P, Van Hazel GA, Jeyarajah R, Martin RCG, Bruns CJ, et al. Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial. Br J Surg. 2019;106(13):1837\u201346.","journal-title":"Br J Surg"},{"issue":"35","key":"4175_CR13","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1200\/JCO.21.01839","volume":"39","author":"MF Mulcahy","year":"2021","unstructured":"Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin RCG 2nd, et al. Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial. J Clin Oncol. 2021;39(35):3897\u2013907.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4175_CR14","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1007\/s00270-011-0234-7","volume":"35","author":"R Seidensticker","year":"2012","unstructured":"Seidensticker R, Denecke T, Kraus P, Seidensticker M, Mohnike K, Fahlke J, et al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol. 2012;35(5):1066\u201373.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"4175_CR15","doi-asserted-by":"publisher","first-page":"614","DOI":"10.21037\/jgo.2017.03.10","volume":"8","author":"A Kennedy","year":"2017","unstructured":"Kennedy A, Cohn M, Coldwell DM, Drooz A, Ehrenwald E, Kaiser A, et al. Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases. J Gastrointest Oncol. 2017;8(4):614\u201324.","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"4175_CR16","first-page":"8","volume":"18","author":"I Kurilova","year":"2019","unstructured":"Kurilova I, Beets-Tan RGH, Flynn J, G\u00f6nen M, Ulaner G, Petre EN, et al. Factors affecting oncologic outcomes of 90Y radioembolization of heavily pre-treated patients with colon cancer liver metastases. Clin Colorectal Cancer. 2019;18(1):8\u201318.","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"4175_CR17","first-page":"296","volume":"14","author":"CT Sofocleous","year":"2015","unstructured":"Sofocleous CT, Violari EG, Sotirchos VS, Shady W, Gonen M, Pandit-Taskar N, et al. Radioembolization as a salvage therapy for heavily pretreated patients with colorectal cancer liver metastases: factors that affect outcomes. Clin Colorectal Cancer. 2015;14(4):296\u2013305.","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"4175_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2967\/jnumed.115.166082","volume":"57","author":"R Hickey","year":"2016","unstructured":"Hickey R, Lewandowski RJ, Prudhomme T, Ehrenwald E, Baigorri B, Critchfield J, et al. 90Y radioembolization of colorectal hepatic metastases using glass microspheres: safety and survival outcomes from a 531-patient multicenter study. J Nucl Med. 2016;57(5):665\u201371.","journal-title":"J Nucl Med"},{"issue":"2","key":"4175_CR19","first-page":"134","volume":"6","author":"AS Kennedy","year":"2015","unstructured":"Kennedy AS, Ball D, Cohen SJ, Cohn M, Coldwell DM, Drooz A, et al. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres. J Gastrointest Oncol. 2015;6(2):134\u201342.","journal-title":"J Gastrointest Oncol"},{"issue":"12","key":"4175_CR20","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.jvir.2023.08.031","volume":"34","author":"PW Doyle","year":"2023","unstructured":"Doyle PW, Workman CS, Shah N, McGonigle TW, Grice JV, Huang S, et al. Predictive partition dosimetry and outcomes after yttrium-90 resin microsphere radioembolization of colorectal cancer metastatic to the liver: a retrospective analysis. J Vasc Interv Radiol. 2023;34(12):2138\u201346.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"4175_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13550-018-0419-z","volume":"8","author":"H Levillain","year":"2018","unstructured":"Levillain H, Duran Derijckere I, Marin G, Guiot T, Vouche M, Reynaert N, et al. (90)Y-PET\/CT-based dosimetry after selective internal radiation therapy predicts outcome in patients with liver metastases from colorectal cancer. EJNMMI Res. 2018;8(1):60.","journal-title":"EJNMMI Res"},{"issue":"7","key":"4175_CR22","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2967\/jnumed.115.166942","volume":"57","author":"AF van den Hoven","year":"2016","unstructured":"van den Hoven AF, Rosenbaum CE, Elias SG, de Jong HW, Koopman M, Verkooijen HM, et al. Insights into the dose-response relationship of radioembolization with resin 90Y-microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Nucl Med. 2016;57(7):1014\u20139.","journal-title":"J Nucl Med"},{"issue":"11","key":"4175_CR23","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.2967\/jnumed.120.255745","volume":"62","author":"AA Alsultan","year":"2021","unstructured":"Alsultan AA, van Roekel C, Barentsz MW, Smits MLJ, Kunnen B, Koopman M, et al. Dose-response and dose-toxicity relationships for glass (90)Y radioembolization in patients with liver metastases from colorectal cancer. J Nucl Med. 2021;62(11):1616\u201323.","journal-title":"J Nucl Med"},{"issue":"4","key":"4175_CR24","first-page":"285","volume":"21","author":"N Schaefer","year":"2022","unstructured":"Schaefer N, Gr\u00f6zinger G, Pech M, Pfammatter T, Soydal C, Arnold D, et al. Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: results from the multicentre observational study CIRT. Clin Colorectal Cancer. 2022;21(4):285\u201396.","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"4175_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13550-017-0292-1","volume":"7","author":"KP Willowson","year":"2017","unstructured":"Willowson KP, Hayes AR, Chan DLH, Tapner M, Bernard EJ, Maher R, et al. Clinical and imaging-based prognostic factors in radioembolisation of liver metastases from colorectal cancer: a retrospective exploratory analysis. EJNMMI Res. 2017;7(1):46.","journal-title":"EJNMMI Res"},{"issue":"4","key":"4175_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/MNM.0000000000001813","volume":"45","author":"S Kesim","year":"2024","unstructured":"Kesim S, Balaban Genc ZC, Soydemir E, Baltacioglu F, Kissa TN, Ozdemir B, et al. Evaluating therapeutic efficacy of extended shelf-life 90Y glass microspheres in transarterial radioembolization for colorectal cancer: a quantitative FDG PET\/CT analysis. Nucl Med Commun. 2024;45(4):268\u201377.","journal-title":"Nucl Med Commun"},{"issue":"9","key":"4175_CR27","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.jvir.2023.05.022","volume":"34","author":"N Naydenov","year":"2023","unstructured":"Naydenov N, Teplov A, Zirakchian MZ, Ruan S, Chu BP, Serencsits B, et al. Yttrium-90 activity quantification in pet\/ct-guided biopsy specimens from colorectal hepatic metastases immediately after transarterial radioembolization using micro-CT and autoradiography. J Vasc Interv Radiol. 2023;34(9):1556-64.e4.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"4175_CR28","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","volume":"48","author":"H Levillain","year":"2021","unstructured":"Levillain H, Bagni O, Deroose CM, Dieudonn\u00e9 A, Gnesin S, Grosser OS, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48(5):1570\u201384.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"4175_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/RLU.0000000000005565","volume":"50","author":"PM Dimopoulos","year":"2025","unstructured":"Dimopoulos PM, Sotirchos VS, Dunne-Jaffe C, Petre EN, Gonen M, Zhao K, et al. Voxel-based dosimetry predicts local tumor progression post 90Y radiation segmentectomy of colorectal liver metastases. Clin Nucl Med. 2025;50(2):133\u201342.","journal-title":"Clin Nucl Med"},{"issue":"8","key":"4175_CR30","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2967\/jnumed.114.153346","volume":"56","author":"VL Gates","year":"2015","unstructured":"Gates VL, Singh N, Lewandowski RJ, Spies S, Salem R. Intraarterial hepatic SPECT\/CT imaging using 99mTc-macroaggregated albumin in preparation for radioembolization. J Nucl Med. 2015;56(8):1157\u201362.","journal-title":"J Nucl Med"},{"issue":"2","key":"4175_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"Suppl 1(Suppl 1","key":"4175_CR32","doi-asserted-by":"publisher","first-page":"122s","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1(Suppl 1)):122s-s150.","journal-title":"J Nucl Med"},{"issue":"8","key":"4175_CR33","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1007\/s00270-017-1703-4","volume":"40","author":"DK Filippiadis","year":"2017","unstructured":"Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol. 2017;40(8):1141\u20136.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4175_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.29083","author":"V Sevilimedu","year":"2023","unstructured":"Sevilimedu V, Pangan G, Pinker K. A review of the estimation of sensitivity and specificity in the context of time-dependent outcomes. J Magn Reson Imaging. 2023. https:\/\/doi.org\/10.1002\/jmri.29083.","journal-title":"J Magn Reson Imaging"},{"issue":"3","key":"4175_CR35","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1148\/radiol.2020191606","volume":"296","author":"AL Hermann","year":"2020","unstructured":"Hermann AL, Dieudonn\u00e9 A, Ronot M, Sanchez M, Pereira H, Chatellier G, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with (90)Y in the SARAH study. Radiology. 2020;296(3):673\u201384.","journal-title":"Radiology"},{"issue":"1","key":"4175_CR36","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1186\/s12885-022-10401-0","volume":"22","author":"N Fidelman","year":"2022","unstructured":"Fidelman N, Atreya CE, Griffith M, Milloy MA, Carnevale J, Cinar P, et al. Phase I prospective trial of TAS-102 (trifluridine and tipiracil) and radioembolization with (90)Y resin microspheres for chemo-refractory colorectal liver metastases. BMC Cancer. 2022;22(1):1307.","journal-title":"BMC Cancer"},{"issue":"9","key":"4175_CR37","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s00330-015-3658-7","volume":"25","author":"WP Fendler","year":"2015","unstructured":"Fendler WP, Ilhan H, Paprottka PM, Jakobs TF, Heinemann V, Bartenstein P, et al. Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer. Eur Radiol. 2015;25(9):2693\u2013700.","journal-title":"Eur Radiol"},{"issue":"23","key":"4175_CR38","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1200\/JCO.2010.28.5643","volume":"28","author":"A Hendlisz","year":"2010","unstructured":"Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28(23):3687\u201394.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4175_CR39","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/jso.20141","volume":"88","author":"G Van Hazel","year":"2004","unstructured":"Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil\/leucovorin chemotherapy versus fluorouracil\/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88(2):78\u201385.","journal-title":"J Surg Oncol"},{"issue":"12","key":"4175_CR40","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1023\/A:1013569329846","volume":"12","author":"B Gray","year":"2001","unstructured":"Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711\u201320.","journal-title":"Ann Oncol"},{"issue":"4","key":"4175_CR41","first-page":"e617","volume":"17","author":"P Gibbs","year":"2018","unstructured":"Gibbs P, Heinemann V, Sharma NK, Taieb J, Ricke J, Peeters M, et al. Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: combined analysis of two randomized controlled studies. Clin Colorectal Cancer. 2018;17(4):e617\u201329.","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"4175_CR42","first-page":"27","volume":"13","author":"CT Sofocleous","year":"2014","unstructured":"Sofocleous CT, Garcia AR, Pandit-Taskar N, Do KG, Brody LA, Petre EN, et al. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin Colorectal Cancer. 2014;13(1):27\u201336.","journal-title":"Clin Colorectal Cancer"},{"issue":"7","key":"4175_CR43","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.jvir.2024.04.010","volume":"35","author":"Y Kitsel","year":"2024","unstructured":"Kitsel Y, Vakiani E, Kirov A, Zirakchian Zadeh M, Kunin H, Petre EN, et al. Histopathologic Changes after Yttrium-90 Radioembolization of Colorectal Liver Metastases: A Pilot Feasibility Study. J Vasc Interv Radiol. 2024;35(7):1012-21.e1.","journal-title":"J Vasc Interv Radiol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04175-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-025-04175-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04175-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T16:56:42Z","timestamp":1767027402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-025-04175-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["4175"],"URL":"https:\/\/doi.org\/10.1007\/s00270-025-04175-8","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Constantinos T. Sofocleous receives research support from SIRTEX Medical, Boston Scientific, Ethicon Inc.\/ NeuWave, Varian Medical Systems; declares consultancy\/advisory boards: -J&J\/Ethicon, Inc., -Terumo Medical Corporation, -BTG Specialty Pharmaceuticals\/Boston Scientific, -SIRTEX Medical, -Varian Medical Systems. No other potential conflicts of interest relevant to this article exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Institutional Review Board waiver of approval was obtained for this retrospective analysis of a prospectively established and maintained HIPAA-compliant clinical database of TARE of CLM. The study encompassed patients with CLM treated with TARE between 9\/15\/2009 and 7\/7\/2023.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional Review Board Statement"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}